The anti-angiogenic basis of metronomic chemotherapy

By R. Kerbel, B. Kamen. Nature Reviews. Cancer, 2004

1,425 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/52bae3d0f5fc3fc6201046c98298b1a49d51c718

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Rakesh K. Jain
2. Peter Carmeliet
3. J. Folkman
4. P. Mancuso
5. F. Bertolini
6. Y. Shaked
7. R. Kerbel

In Molecular Biology

1. Rakesh K. Jain
2. N. Ferrara
3. Peter Carmeliet
4. Dai Fukumura
5. J. Folkman
6. R. Kerbel
7. P. Mancuso
8. F. Bertolini

In Oncology

1. Rakesh K. Jain
2. N. Ferrara
3. Dai Fukumura
4. Peter Carmeliet
5. R. Kerbel
6. J. Folkman
7. P. Mancuso
8. F. Bertolini

Citations in the corpus

• Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. (2006, background): “These approaches include Avastin plus Tarceva or Avastin plus antiangiogenic chemotherapy [19] (metronomic chemotherapy) [20].”
• Combination therapy in combating cancer (2017, background): “Here, chronic administration of a low dose of drugs with anti-angiogenic properties is an effective strategy in cancer treatment [153, 154].”
• Cytokines in Cancer Immunotherapy (2011, background): “At low doses, IFN- acts as an anti-angiogenic agent [32].”
• The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006, methodology): “have indicated that the counting of CECs and CEPs can be used to identify OBD in cancer-bearing mice treated with low-dose metronomic chemotherapy , a promising therapeutic cancer treatment strategy thought to have an anti-angiogenic basi”
• Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach (2006, background): “Low-dose clodrolip therapy applied at higher frequency, also termed ‘metronomic’ therapy (Kerbel and Kamen, 2004), might be superior to conventional maximal tolerated dose regimens and further improve TAM and TADC depletion.”
• Metronomic chemotherapy: new rationale for new directions (2010, background): “An alternative to these angiogenesis inhibitors that is generating clinical interest is metronomic chemotherapy”
• Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics (2009, neutral): “…doses on a more frequent and regular dosing interval prevents bone marrow toxicity and blocks tumor growth by interfering with angiogenesis (Hahnfeldt et al., 2003), which was thought to result from either inducing apoptosis or decreasing proliferation of endothelial cells (Kerbel and Kamen, 2004).”
• Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. (2007, background): “…therapies, certain doses and schedules of cytotoxic therapies such as chemotherapy and radiation therapy have been shown to exhibit antiangiogenic activity via the direct cytotoxic effect on proliferating vascular endothelial cells (Garcia-Barros et al., 2003; Kerbel and Kamen, 2004).”
• Angiogenesis as a therapeutic target (2005, background): “Because VEGF-A acts as a mobilizing and probably a survival agent for such cells, co-administration of a VEGF-targeting agent, especially one with a long half-life in the circulation (for example, anti-VEGF antibodies), would be expected to amplify and sustain the suppressive effects of standard (as”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “On the basis of a postulated effect on angiogenesis and/or stroma, low-dose, metronomic chemotherapy has been studied in advanced disease [64, 65].”
• Angiogenesis in life, disease and medicine (2005, background): “Chemotherapeutics, which target dividing cells, may also inhibit EC growth when delivered in metronomic regimens (that is, a continuous low dose”